Alder Biopharmaceuticals Inc., commonly referred to as Alder, is a prominent biopharmaceutical company headquartered in the United States. Founded in 2002, Alder has established itself within the biotechnology industry, focusing primarily on the development of innovative therapies for migraine prevention and other neurological conditions. The company’s flagship product, ALD518, is a monoclonal antibody designed to target and inhibit specific pathways involved in migraine pathophysiology, setting it apart in a competitive market. Alder's commitment to advancing patient care has led to significant milestones, including successful clinical trials and partnerships that enhance its market position. With a strong emphasis on research and development, Alder Biopharmaceuticals continues to make strides in delivering unique therapeutic solutions to improve the quality of life for patients worldwide.
We don't have data for Alder Biopharmaceuticals Inc., ALD518, but we can show you information about their parent organization instead.
View parent company